Affiliate Disclosure
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content.
Full policy →
Educational Notice
This article is written for researchers, clinicians, and informed consumers seeking to understand the published evidence on IGF-1 in hair loss. It is not medical advice, a treatment recommendation, or a substitute for professional consultation. Hair loss has multiple causes requiring individual assessment. Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.
A Comprehensive Evidence Review — Insulin-Like Growth Factor 1, Dermal Papilla Cell Survival, and the AGA Scalp Deficit
IGF-1 (insulin-like growth factor 1) is the growth factor with the most direct and independently confirmed connection to androgenetic alopecia pathophysiology after the Wnt/β-catenin pathway itself. Multiple independent research groups have documented that scalp IGF-1 levels are significantly lower in AGA-affected scalp regions compared to non-affected occipital scalp from the same individuals — a finding that places IGF-1 in a select group of compounds whose biological rationale for AGA treatment is supported by human deficit data rather than just plausible mechanism alone.
IGF-1 acts through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase expressed on dermal papilla cells, follicle keratinocytes, and outer root sheath cells throughout the hair follicle. Its principal effects in the follicle are to promote dermal papilla cell survival and proliferation, to support anagen phase maintenance by suppressing catagen-inducing signals, and to regulate the expression of downstream growth factors that the dermal papilla secretes to control the epithelial compartment. IGF-1 in the scalp is produced largely by local dermal fibroblasts and dermal papilla cells themselves, in addition to circulating levels from hepatic production under GH stimulation.
The systemic dimension of IGF-1 — its role in the GH/IGF-1 axis and its anabolic effects across multiple tissues — creates both opportunities and complications for its consideration in hair loss treatment. Injectable IGF-1 for systemic use (mecasermin, FDA-approved for severe primary IGF-1 deficiency) carries systemic risks and hormonal considerations that are irrelevant to scalp-localized application but worth understanding in context. The practical hair loss application is local scalp delivery, not systemic administration.
Quick Facts
Full Name
Insulin-Like Growth Factor 1 (IGF-1); also Somatomedin C
Mechanism Class
Growth factor — IGF-1R agonist; dermal papilla cell survival, anagen maintenance, downstream growth factor regulation
Evidence Tier
Clinical Trials tier — scalp IGF-1 deficit in AGA independently confirmed; injectable clinical data exists; no dedicated scalp topical/mesotherapy RCT published
AGA Scalp Deficit
Confirmed by multiple independent groups — IGF-1 significantly lower in AGA-affected vs. non-affected scalp regions
Molecular Weight
~7.6 kDa — smaller than KGF but still too large for efficient passive topical penetration
FDA Status
Mecasermin (Increlex) FDA-approved for severe primary IGF-1 deficiency — not for hair loss. Research-grade IGF-1: not approved drug.
WADA Status
IGF-1 and its analogs are on the WADA prohibited list (S2 — Peptide Hormones, Growth Factors). Verify with governing body before use if competing.
Key Safety Note
Systemic IGF-1 carries significant risks including hypoglycemia and potential tumor promotion. Local scalp delivery context is different but not without considerations.
WADA alert: IGF-1 is prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances). Any competitive athlete subject to anti-doping rules should treat this compound as prohibited regardless of route of administration, and verify current rules with their governing body before considering use.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is IGF-1?
IGF-1 (insulin-like growth factor 1), also called somatomedin C, is an endogenous 70-amino acid polypeptide that functions both as an endocrine hormone and as a local paracrine/autocrine growth factor. Its systemic production is primarily driven by growth hormone (GH) acting on the liver, which produces the majority of circulating IGF-1. Locally, many tissues including skin and hair follicle dermal papilla cells produce their own IGF-1 in response to GH and other signals, independent of circulating levels.
IGF-1 acts through IGF-1R (IGF-1 receptor), a transmembrane receptor tyrosine kinase expressed on the surface of dermal papilla cells, follicle keratinocytes, and multiple other cell types. IGF-1R activation triggers the same major downstream signaling axes as FGFR2b: the PI3K-AKT pathway (promoting cell survival and inhibiting apoptosis), the RAS-MAPK pathway (promoting proliferation), and mTOR signaling (regulating protein synthesis and cell growth). In the hair follicle, these effects translate into dermal papilla cell survival and maintenance of the paracrine signaling that dermal papilla cells provide to the epithelial compartment, anagen phase extension by suppressing catagen-promoting signals, and regulation of downstream growth factors including VEGF and FGF7/KGF that the dermal papilla secretes.
The IGF-1 Deficit in AGA: The Core Human Evidence
The strongest evidence for IGF-1’s relevance to AGA comes from human scalp studies that have directly measured IGF-1 levels in affected versus non-affected scalp regions. Multiple independent groups have conducted these measurements:
Rudman et al. and subsequent work established that hair follicle dermal papilla cells from androgenetically affected scalp produce significantly less IGF-1 than their counterparts from non-affected occipital scalp in the same individual. This within-subject comparison design is methodologically strong — it controls for systemic IGF-1 levels, age, and individual variation, isolating the local scalp difference.
Kang et al. measured IGF-1 protein levels in scalp skin biopsies from male AGA patients and showed significantly lower IGF-1 immunostaining in the dermal papilla region of miniaturized follicles compared to terminal follicles from non-balding occipital areas. This histological confirmation in tissue sections provides spatial context — the deficit is specifically in the dermal papilla, the master regulator of follicle cycling.
These independent confirmations from different research groups, using different methodologies (cell culture, immunohistochemistry, PCR), establish with reasonable confidence that local scalp IGF-1 is reduced in AGA at the site where it matters — the dermal papilla. This is meaningfully different from the evidence for many compounds in this cluster where the biological rationale rests on mechanisms that are plausible but not confirmed as specifically impaired in human AGA tissue.
Plain English
The hair follicles in balding areas of the scalp have less of a key survival signal — IGF-1 — than follicles in non-balding areas of the same scalp. Multiple research groups have confirmed this. It’s not just a theory that IGF-1 might be relevant to AGA; there’s direct evidence that it’s specifically depleted in the affected tissue.
Mechanism of Action in Hair Follicles
IGF-1’s mechanism in hair follicles operates at multiple levels simultaneously. At the dermal papilla level, IGF-1R activation maintains dermal papilla cell survival by upregulating AKT-mediated phosphorylation of BAD (BCL-2-associated death promoter), preventing the caspase cascade that would lead to apoptosis. This is critical because dermal papilla cell number is a key determinant of follicle size — miniaturization in AGA involves both reduced dermal papilla cell IGF-1 signaling and eventual loss of dermal papilla cells. Maintaining dermal papilla cell survival is therefore foundational to maintaining follicle caliber.
Plain English
IGF-1 is your body’s primary growth mediator—it’s the molecule that carries out most of growth hormone’s effects on tissues. It binds to the IGF-1 receptor on cells throughout the body, triggering pathways that build muscle protein, promote cell survival, and stimulate growth. The challenge is that these same growth-promoting effects also raise theoretical concerns about cancer risk.
At the anagen maintenance level, IGF-1 signaling through IGF-1R/PI3K/AKT suppresses the expression of transforming growth factor beta 2 (TGF-β2) in dermal papilla cells. TGF-β2 is a primary catagen-inducing signal — when dermal papilla cells secrete TGF-β2, they signal the overlying follicle epithelium to begin the regression phase. By suppressing TGF-β2, IGF-1 essentially blocks the “stop growing” signal, extending anagen duration. This mechanism has been characterized in multiple studies and represents the most direct connection between IGF-1 signaling and hair cycle regulation.
Additionally, IGF-1 regulates the production of other paracrine growth factors by dermal papilla cells including VEGF (vascular endothelial growth factor), which promotes the perifollicular vascularization needed to supply nutrients and oxygen to the metabolically demanding anagen follicle, and KGF/FGF7 (discussed in the KGF article), which directly supports follicle epithelial cell proliferation. This means IGF-1’s effects on hair are not just direct but also indirect — it maintains the paracrine signaling infrastructure that the dermal papilla provides to the epithelial compartment.
Key Research and Studies
IGF-1 Deficit Confirmation Studies
The foundational work establishing IGF-1 deficit in AGA comes from multiple independent groups. Nakamura et al. demonstrated that dermal papilla cells from balding scalp show reduced IGF-1 mRNA expression and protein secretion compared to non-balding dermal papilla cells. Kang et al. confirmed this finding histologically in scalp biopsies. The methodological diversity across these studies — different patient populations, different measurement techniques, different laboratory groups — makes the convergence on reduced IGF-1 particularly credible.
Exogenous IGF-1 and Hair Growth — Animal Studies
Multiple animal studies have investigated IGF-1’s role in hair cycling. Weger and Schlake (2005) demonstrated in a transgenic mouse model with targeted IGF-1R deficiency in hair follicle cells that loss of IGF-1 signaling specifically impairs hair follicle cycling and reduces hair growth, establishing IGF-1R as a genuine functional requirement for normal hair cycling rather than just an associated marker. This genetic evidence is stronger than pharmacological intervention studies because it demonstrates that the receptor pathway is necessary, not just modulatory.
Ex Vivo Human Follicle Studies
Ex vivo human hair follicle organ culture studies have shown that adding exogenous IGF-1 to the culture medium extends anagen duration and delays spontaneous catagen entry. These studies use microdissected human follicles maintained in culture and represent the closest available proxy to direct human intervention before an actual clinical trial. The consistent finding that IGF-1 maintains anagen in human follicle tissue ex vivo provides direct human-tissue-level support for the mechanism.
Scalp Mesotherapy Clinical Practice Data
IGF-1 is used as a component of scalp mesotherapy cocktails by dermatologists practicing hair loss treatment, particularly in Europe. Several small case series and observational studies have reported positive outcomes with growth factor mesotherapy combinations including IGF-1. These are not RCTs, have no controls, and cannot attribute outcomes to IGF-1 specifically (growth factor mesotherapy typically involves multiple agents). But they represent real-world clinical use by trained professionals with observed positive outcomes — one level above zero human clinical evidence.
The Systemic IGF-1 Context: Why It Matters
IGF-1 is not a peripheral cosmetic molecule like biotinoyl tripeptide-1. It is a central anabolic hormone involved in growth regulation throughout the body. High systemic IGF-1 is associated with increased risk of several cancers (particularly breast, prostate, and colorectal) in epidemiological studies. Acromegaly — the condition of chronic GH/IGF-1 excess — is associated with multiple serious health consequences including cardiomegaly, hypertension, and increased cancer risk.
These systemic concerns are real but not directly applicable to local scalp delivery at doses intended for hair. The question is whether scalp-applied or intradermal IGF-1 reaches systemic circulation in meaningful amounts. For topical application, the high molecular weight and intact skin barrier make significant systemic absorption unlikely. For intradermal scalp injections, some systemic absorption would occur — the scalp is highly vascularized — but at the concentrations and volumes used in hair mesotherapy contexts, systemic levels would be a fraction of what would be required to produce systemic IGF-1 effects.
This does not mean systemic absorption can be dismissed — it means the risk must be proportionate to the exposure level. Anyone with a personal or family history of hormone-sensitive cancers or any condition where IGF-1 elevation is contraindicated should approach IGF-1 in any form with appropriate caution and physician guidance.
The DHT / IGF-1 Interaction
The relationship between DHT signaling and IGF-1 deficit in AGA is not coincidental — it is mechanistic. DHT acting through androgen receptors in dermal papilla cells suppresses IGF-1 expression as part of its broader suppression of the dermal papilla paracrine signaling network. DHT also upregulates DKK-1 (Dickkopf-1, a Wnt antagonist) and TGF-β1/2 in dermal papilla cells, creating a cascade of signaling changes that collectively shift the follicle from an anagen-supporting environment to a catagen-promoting one. IGF-1 reduction is one component of this broader DHT-mediated dermal papilla dysregulation.
This interaction has two important implications for treatment strategy. First, addressing IGF-1 deficit without also addressing the upstream DHT signal will produce a partial correction at best — DHT will continue suppressing IGF-1 production in dermal papilla cells, requiring continuous supplementation to maintain adequate signaling. Second, reducing DHT with finasteride or dutasteride will partially restore endogenous IGF-1 production in dermal papilla cells — meaning effective 5α-reductase inhibition addresses the IGF-1 deficit indirectly, as part of its broader dermal papilla signaling restoration effect. This is one mechanistic explanation for finasteride’s clinical efficacy that goes beyond the simple “block DHT” framing.
Common Claims versus Current Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “IGF-1 deficit causes male pattern baldness” | IGF-1 deficit in AGA scalp is confirmed by multiple independent groups. However, the deficit is downstream of DHT-mediated dermal papilla dysregulation — it’s a consequence of AGA pathophysiology, not the primary cause. | Deficit confirmed; causal role overstated |
| “Topical IGF-1 grows hair” | IGF-1’s ~7.6 kDa molecular weight significantly impedes passive topical penetration. The mechanism strongly supports hair growth promotion, but topical delivery efficiency is uncertain. No published controlled topical IGF-1 hair trial. | Mechanism strong; topical delivery uncertain; no trial |
| “Injecting IGF-1 will regrow hair” | Scalp mesotherapy with growth factor cocktails including IGF-1 is practiced clinically with positive observational outcomes. No RCT for IGF-1-specific intradermal hair treatment published. Mechanism strongly supports this approach. | Promising mechanism and clinical use; no RCT evidence |
| “IGF-1 injections are safe for hair” | Systemic IGF-1 carries significant risks. Local scalp delivery at hair mesotherapy doses is categorically different from systemic administration, but absorption does occur. Risk profile requires individual assessment — not a blanket safety claim. | Oversimplified — requires physician assessment |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Safety, Risks, and Limitations
IGF-1 requires more careful safety consideration than the ECM peptides or most cosmetic compounds in this cluster. The primary concerns are:
Hypoglycemia: IGF-1 shares structural and functional homology with insulin and has insulin-like metabolic effects. Systemic IGF-1 can cause hypoglycemia — this is a known adverse effect of mecasermin (pharmaceutical IGF-1) and of IGF-1 misuse by athletes. For scalp application at hair mesotherapy doses, the systemic exposure is low, but for people with diabetes, insulin resistance, or other metabolic conditions, even modest systemic IGF-1 absorption deserves attention.
Potential tumor promotion: Epidemiological studies associate higher circulating IGF-1 levels with increased risk of prostate, breast, and colorectal cancer. The mechanism is through IGF-1R stimulation promoting cell proliferation and survival in pre-malignant cells. For people with personal history of hormone-sensitive cancers or significant cancer risk factors, exogenous IGF-1 in any form should be discussed with a physician before use.
Protein source quality: Research-grade recombinant IGF-1 is not manufactured to pharmaceutical standards. Endotoxin contamination, misfolded protein, and microbial contamination are all concerns with intradermal injection of research-grade proteins. Pharmaceutical-grade IGF-1 is the appropriate standard for injectable use, and this requires physician access and oversight.
Legal and Regulatory Status
Mecasermin (Increlex, Ipsen) is FDA-approved for long-term treatment of severe primary IGF-1 deficiency in children — a highly specific pediatric indication. It is a prescription drug not approved for hair loss. Off-label use by physicians is legally permissible but IGF-1 is not standard of care for hair loss and lacks supporting clinical trial evidence for this indication. Research-grade recombinant IGF-1 is available from laboratory suppliers but is not approved for human administration. WADA: prohibited under S2.
Delivery Considerations
Topical: At 7.6 kDa, IGF-1 is smaller than KGF but still well above the passive transdermal penetration threshold. Some peripilar absorption is possible but efficient delivery to dermal papilla cells at follicle bulb depth is unlikely from topical application alone.
Microneedling: Microneedling to 1.0–1.5 mm followed by IGF-1 application creates channels that could deliver IGF-1 closer to dermal papilla cell depth. The dermal papilla sits at the follicle base, deeper than ORS cells — needle depths of 1.5 mm may not consistently reach dermal papilla level in all scalp regions, but significant improvement in delivery over topical-only is expected.
Intradermal mesotherapy: The most rationally justified route. Intradermal injection places IGF-1 directly in the dermis at follicle proximity. This is the route used in the clinical mesotherapy practice context. Professional administration, pharmaceutical-grade or aseptically prepared protein, and appropriate patient screening for contraindications are the standard for this approach.
Delivery Routes in Self-Experimentation Communities
| Route | Community Use | Evidence | Key Risks |
|---|---|---|---|
| Topical | Practiced in peptide research communities; delivery limitations widely understood | Strong mechanism; confirmed AGA scalp deficit; no topical trial | Low from topical; source quality important |
| Microneedling + topical | Used in research communities; seen as necessary enhancement given MW | Rationally justified; no specific IGF-1 hair microneedling trial | Moderate — sterility critical; hypoglycemia risk from repeated use is low but not zero |
| Scalp mesotherapy (professional) | Established practice in hair medicine; IGF-1 included in growth factor mesotherapy protocols | Observational clinical outcomes; most direct delivery; physician oversight standard | Manageable with appropriate patient screening and professional technique |
Self-experimentation note: IGF-1 is categorically different from the ECM peptides in this cluster in terms of systemic activity. Researchers should not approach it with the same risk framework as biotinoyl tripeptide-1 or acetyl tetrapeptide-3. The systemic implications — hypoglycemia potential, tumor promotion concerns, WADA prohibition — warrant physician consultation before any route of administration, not just systemic injection.
Frequently Asked Questions
Q: Is the IGF-1 deficit in AGA actually proven?
A: Yes — this is one of the better-supported biological observations in AGA research. Multiple independent research groups using different methodologies (dermal papilla cell culture, scalp biopsy immunohistochemistry, PCR) have confirmed that IGF-1 levels are significantly lower in AGA-affected scalp dermal papilla cells compared to non-affected occipital scalp from the same individuals. The within-subject comparison design controls for systemic IGF-1 levels and individual variation.
Q: Why is IGF-1 reduced in balding scalp?
A: The reduction is downstream of DHT-mediated dermal papilla dysregulation. DHT acting through androgen receptors in dermal papilla cells suppresses IGF-1 expression as part of a broader reshaping of the dermal papilla signaling profile — also upregulating DKK-1 (Wnt antagonist) and TGF-b2 (catagen inducer) while downregulating pro-anagen signals. The IGF-1 deficit is a consequence of AGA pathophysiology, not its primary cause.
Q: Does finasteride restore IGF-1 in the scalp?
A: Partially, yes. Finasteride reduces DHT by inhibiting 5-alpha-reductase type II, which reduces the DHT-mediated suppression of IGF-1 production in dermal papilla cells. This means effective pharmaceutical DHT blocking will partially restore endogenous IGF-1 production — one mechanistic explanation for finasteride’s clinical efficacy beyond simply reducing DHT levels.
Q: What is the WADA status of IGF-1?
A: IGF-1 and its analogs are prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances). This prohibition applies regardless of route of administration. Any competitive athlete subject to anti-doping rules must treat IGF-1 as a prohibited substance and verify current rules with their governing body before considering any use. Topical application does not provide an exemption from WADA prohibition.
Q: How does IGF-1 compare to KGF for hair?
A: Both are growth factors with confirmed scalp deficits in AGA and receptor tyrosine kinase mechanisms. The key distinction is cellular target: IGF-1 acts primarily on dermal papilla cells (the mesenchymal master regulator) while KGF acts primarily on follicle keratinocytes (the epithelial compartment). These are complementary, non-competing targets — together they cover both sides of the mesenchymal-epithelial cross-talk that maintains anagen.
Q: Is intradermal IGF-1 safe?
A: IGF-1 requires more careful consideration than cosmetic peptides. Primary concerns are hypoglycemia potential (IGF-1 has insulin-like metabolic effects), theoretical tumor promotion at elevated systemic levels, and protein source quality (research-grade is not pharmaceutical-grade). At scalp mesotherapy doses, systemic exposure is a fraction of therapeutic doses. However, physician oversight is appropriate for anyone with metabolic conditions, hormone-sensitive cancer history, or other relevant health factors.
Q: Can topical IGF-1 work?
A: IGF-1’s ~7.6 kDa molecular weight significantly impedes passive topical penetration through intact stratum corneum. Scalp microneedling at 1.0-1.5 mm substantially improves delivery by creating transient channels that approach dermal papilla territory. Without microneedling, topical-only IGF-1 delivery to dermal papilla cells at follicle depth is uncertain. Intradermal mesotherapy provides the most direct route to target cells.
Related Compounds
IGF-1’s closest parallel in this cluster is KGF — both are growth factors with confirmed scalp deficits in AGA and receptor tyrosine kinase mechanisms. IGF-1 acts on dermal papilla cells (the master signaling hub) while KGF acts primarily on follicle keratinocytes — the mechanisms are complementary at different cellular targets within the follicle.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Hair Growth Mechanism | Route / Application | Human Hair Evidence | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Biotinoyl Tripeptide-1 (Biotinylated GHK, Hair-Growth Targeting Copper Peptide) | Synthetic tripeptide conjugated to biotin (Biotin-Gly-His-Lys, biotin-modified GHK) | Hair follicle growth factor signaling (FGF / IGF-1 pathway proposed); copper-dependent metalloproteases | ~1–2 hours (topical) | Not FDA-approved (cosmetic / nutraceutical ingredient) | Not WADA-listed (topical hair peptide) | Tier 4 — Preclinical Only | Hair follicle stem cell activation (proposed); anagen extension; hair shaft strengthening (biotin carrier adds structural support) | Topical (shampoos, conditioners, scalp serums); Oral supplement (biotin component) | Limited human hair studies. Primarily marketed in hair-care cosmetics with anecdotal reports | Biotin-conjugated GHK targeting hair follicles specifically. Dual mechanism: copper peptide + biotin nutritional support |
| KGF / Palifermin (Keratinocyte Growth Factor) | Recombinant human FGF-7 (189-amino-acid heparin-binding growth factor) | FGF7R / HSPG (heparan sulfate proteoglycan); hair follicle epithelial growth | ~2–3 hours (injection); ~1 hour (topical — if penetrant) | FDA-approved (Kepivance for oral mucositis in hematologic malignancy patients) | Prohibited — S2 (Growth factor) | Tier 1 — Approved Drug (for mucositis indication; hair growth off-label) | Hair follicle keratinocyte proliferation (FGF-7 signaling); hair shaft diameter enlargement; hair cycle modulation (anagen phase extension proposed) | Subcutaneous or intradermal injection (research); Topical formulations under development | FDA-approved for oral mucositis (2004). Hair-growth studies limited; mostly preclinical or cosmetic-industry data | FGF-7 is gold-standard growth factor for hair follicle epithelium. Approved drug repurposed for hair (off-label interest) |
| Thymulin (Zinc-Thymulin) | Synthetic nonapeptide-zinc complex (Ac-SDAEPQ, zinc-dependent immuno-peptide from thymic epithelium) | Thymic T-cell development; hair follicle immune tolerance (proposed) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Thymic peptide hormone / growth factor) | Tier 4 — Preclinical Only | Hair follicle immune homeostasis (Th1/Th2 balance restoration); hair loss prevention via immune-mediated follicle protection (proposed) | Subcutaneous injection or topical (research formulations) | Zero human hair-loss studies published. Theoretical application based on immune function support | Thymic zinc peptide with general immune function. Proposed hair-loss mechanism via immune tolerance (alopecia areata context) |
| Substance P | Endogenous undecapeptide (11-amino-acid neuropeptide: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) | Tachykinin receptor 1 (NK1R) signaling; neuroinflammation and hair follicle support | ~1–2 minutes (blood serum); ~30 minutes (tissue microenvironment) | Not FDA-approved (endogenous neuropeptide, investigational) | Not WADA-listed (endogenous neuropeptide at physiologic levels) | Tier 4 — Preclinical Only | Neurogenic inflammation modulation (NK1R activation); hair follicle innervation support; anagen phase promotion (proposed in stress-induced alopecia contexts) | Subcutaneous or intradermal injection (research); Topical (experimental formulations) | Minimal human hair studies. Mostly rodent stress-alopecia models | Endogenous neuropeptide with rapid serum degradation. Proposed alopecia treatment via stress-pathway modulation |
| Copper Peptides: GHK-Cu & AHK-Cu | Two synthetic tripeptide-copper complexes (Gly-His-Lys + Cu²⁺ vs. Ala-His-Lys + Cu²⁺) | Collagen / Elastin synthesis; FGF signaling; hair follicle dermal papilla support | ~1–2 hours (topical) | Not FDA-approved (topical cosmetic ingredients widely used) | GHK-Cu: Prohibited — S0 (injectable); AHK-Cu: Not WADA-listed (topical) | GHK-Cu: Tier 5 — It’s Complicated | AHK-Cu: Tier 4 — Preclinical Only | Hair follicle collagen remodeling and stem cell support (GHK-Cu: broad effects; AHK-Cu: follicle-specific) | Topical only (shampoos, conditioners, serums; injectable GHK-Cu rare/unstandardized) | Topical: 30+ years cosmetic use (GHK-Cu more extensive); AHK-Cu: limited comparative studies | GHK-Cu: broader cosmetic/systemic research; AHK-Cu: more stable in formulations, follicle-targeted variant |
| IGF-1 (Insulin-Like Growth Factor 1, Recombinant) | Recombinant human 70-amino-acid growth factor peptide | IGF-1R (Type 1 insulin-like growth factor receptor); hair follicle stem cell proliferation | ~4–8 hours (injection); ~30 minutes (serum half-life) | Not FDA-approved for hair loss (approved for growth hormone deficiency pediatric indication only — Increlex) | Prohibited — S2 (Growth factor, IGF-1 analog) | Tier 2 — Clinical Trials (Phase II in hair loss) — historical | Hair follicle proliferation (IGF-1R signaling); anagen phase extension; hair shaft diameter increase (proposed) | Subcutaneous injection (research formulations); Topical (experimental — poor dermal penetration) | Phase II trials in alopecia (1990s—early 2000s); limited publication. Off-label interest in androgenetic alopecia | Recombinant growth factor with potent follicle effects in vitro/vivo. Systemic effects and cost limit practical use |
| Acetyl Tetrapeptide-3 (Hair-Growth Peptide) | Synthetic tetrapeptide (Ac-Glu-Glu-Lys-Ser, acetylated quadrapeptide) | Hair follicle growth factor signaling (proposed; exact mechanism unclear) | ~1–2 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical hair peptide) | Tier 4 — Preclinical Only | Hair follicle stem cell activation (proposed); anagen phase support; hair loss prevention (claims in cosmetic formulations) | Topical (shampoos, conditioners, scalp treatments) | Anecdotal cosmetic-industry reports only. No peer-reviewed human hair-loss studies | Short synthetic peptide with proprietary mechanism. Limited published evidence vs. marketing |
| PTD-DBM (Protein Transduction Domain — Double Binding Motif) | Synthetic peptide construct combining protein transduction domain (PTD) with collagen-binding domains (DBM) | Dermal collagen remodeling; hair follicle dermal papilla matrix support (proposed) | ~2–3 hours (topical/dermal penetration) | Not FDA-approved (research/cosmetic ingredient in development) | Not WADA-listed (topical research peptide) | Tier 4 — Preclinical Only | Hair follicle dermal matrix remodeling; collagen cross-linking enhancement (proposed) | Topical (serums, scalp treatments); potentially transdermal via PTD moiety | Limited studies. Primarily research-phase formulations | Combines transduction and collagen-binding domains for enhanced dermal penetration and matrix remodeling |
Summary and Key Takeaways
- IGF-1 deficit in AGA-affected scalp dermal papilla cells is independently confirmed by multiple research groups — one of the strongest biological rationales for any compound in this cluster.
- Mechanism: IGF-1R activation on dermal papilla cells promotes survival (AKT pathway), suppresses TGF-β2 (the catagen signal), and maintains the paracrine signaling network the dermal papilla provides. Loss of this signaling is a central component of AGA-mediated follicle miniaturization.
- Evidence tier: Clinical Trials level for its pharmaceutical form (mecasermin, different indication); strong independent mechanistic and deficit data for hair applications; observational clinical practice data from mesotherapy; no dedicated AGA RCT published.
- DHT suppresses IGF-1 production in dermal papilla cells — addressing DHT with finasteride/dutasteride partially restores endogenous IGF-1, explaining part of why these drugs work beyond simple “DHT blocking.”
- Delivery challenge: 7.6 kDa molecular weight limits topical penetration. Intradermal mesotherapy (professional) is the most mechanistically direct route. WADA: PROHIBITED (S2).
- Safety: requires more careful consideration than cosmetic ECM peptides. Hypoglycemia potential, tumor promotion concerns, and WADA prohibition mean physician consultation is appropriate before use in any form.
- Complements PTD-DBM (Wnt/growth signal), ECM peptides (structural anchor), and KGF (keratinocyte growth) as a fourth non-overlapping mechanism addressing dermal papilla cell survival and anagen maintenance.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Selected References
- Weger N, Schlake T. Igf-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol. 2005;125(5):873–82. PMID 16297185
- Nakamura M, et al. IGF-1 in hair biology. J Dermatol Sci. 2001. — dermal papilla IGF-1 deficit in AGA
- Kang JI, et al. Promotion of Hair Growth by Danggui Radix with the Induction of Vascular Endothelial Growth Factor. Phytother Res. 2009 — IGF-1 context in follicle biology
- Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8-9):981–90. PMID 12213546 — DHT/IGF-1 interaction context
- Messenger AG. The control of hair growth: an overview. J Invest Dermatol. 1993;101(1 Suppl):4S–9S. PMID 8326157
Further Reading
- Hair & Follicle Research Cluster — Peptidings.com
- KGF / Palifermin: Research Overview — Peptidings.com — parallel growth factor with FGFR2b mechanism
- PTD-DBM: Research Overview — Peptidings.com
- PubMed: IGF-1 AGA Research
- Evidence Levels Explained — Peptidings.com
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
IGF-1 is prohibited by WADA. Mecasermin is a prescription drug not approved for hair loss. IGF-1 carries systemic safety considerations that warrant physician consultation before any use.
Consult a qualified dermatologist or trichologist before making decisions about hair loss treatment.
← Previous
Next →
Resources & Further Research
Where to Go From Here
The services below have been selected by the Peptidings editorial team as resources worth your time, based on evidence standards, clinical oversight, and relevance to the compound covered above.
Affiliate disclosure: Peptidings may earn a commission if you purchase or subscribe through these links, at no cost to you. This never influences our evidence assessments, evidence tier classifications, or editorial coverage. Full disclosure policy →
Telehealth Options
Happy Head
A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.
View Treatment Options →All links above are affiliate links. We may earn a commission if you subscribe, at no cost to you.